TPO and autoimmune thrombocytopenic purpura: For 49 patients (61%) currently receiving ITP therapy, the main treatments were TPO‐RA (31 [39%]), corticosteroids (12 [15%]), IVIg (6 [8%]) and rituximab (6 [8%]; Table 1).